Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IEV407 alone or with fulvestrant/letrozole in advanced HR-positive HER2-negative breast cancer
jRCT2031260167Recruiting
- Sponsor
- Novartis
- Start
- Oct 2026
- Modality
- Small Molecules
01
Overview
Open-label trial of IEV407 in breast cancer (3 arms), sponsored by Novartis. Primary endpoints: Incidence and severity of dose-limiting toxicities, Incidence and severity of adverse events and serious adverse events and 2 more. Started Oct 2026; status: recruiting.
02
Drugs
IEV407
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031260167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260167.